atezolizumab + cyclophosphamide + doxorubicin

Atezolizumab + cyclophosphamide + doxorubicin is a combination regimen consisting of three agents used in cancer therapy, particularly in breast cancer clinical trials. - **Atezolizumab** is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription, leading to cell death, especially in rapidly dividing cells. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in cytotoxicity against cancer cells. This combination has been investigated for use in triple-negative breast cancer (TNBC) and HER2-positive early breast cancer as part of neoadjuvant or adjuvant regimens[1][2][3][7]. The rationale for combining these drugs includes the potential synergistic effect between immunotherapy (atezolizumab) and chemotherapy (cyclophosphamide and doxorubicin), aiming to improve progression-free survival or pathological complete response rates[1][2]. However, large phase 3 studies have not consistently demonstrated significant benefit over standard chemotherapy alone[2][3][7].

Brand names

TecentriqAdriamycinCytoxan

Other names

pegylated liposomal doxorubicinPLD